Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:22:50.998Z.
Calculation as of: 2026-10-06T17:22:50.998Z.
Quote observation: 2026-10-06T17:19:46.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c752279377b025acf72c3dd079155b3811244be546b74823e0a9f28be94cffb5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$42.63M
EBITDA Yield
N/A
TTM Avg
14.45%
3Y Avg
11.70%
5Y Avg
11.70%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nano-X Imaging Ltd. (NNOX) | $43.70M | N/A | N/A | N/A | N/A |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $43.78M | N/A | N/A | N/A | N/A |
| SANUWAVE Health Inc. (SNWV)vs › | $43.38M | 4.24% | 3.76% | 3.51% | 3.51% |
| CVRx, Inc. (CVRX)vs › | $44.05M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $42.63M | N/A | 14.45% | 11.70% | 11.70% |
| Precipio, Inc. (PRPO)vs › | $42.11M | N/A | 0.46% | 0.46% | 0.46% |
| DarioHealth Corp. (DRIO)vs › | $44.60M | N/A | 8.08% | 7.24% | 6.66% |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $45.17M | N/A | N/A | N/A | N/A |
| Instil Bio, Inc. (TIL)vs › | $46.97M | N/A | N/A | N/A | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.14M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
